The essential finding of this study was that high ex vivo phosphorylation of PI3K-related substrates by the primary tumor, rather than the KRAS/BRAF mutation status, may be a hallmark of poor metastasis-free survival in LARC patients after radical treatment of the pelvic cavity. Here, KRAS is linked to neoplasm.